Abstracts tagged "lung and scleroderma"

Abstract Number: 1682 • 2017 ACR/ARHP Annual Meeting
Significance of Anti-Topoisomerase I Antibodies in Routine Clinical Testing
Anne E Tebo¹, Robert L. Schmidt² and Tracy M. Frech³, ¹University of Utah, Salt Lake City, UT, ²Pathology, University of Utah, Salt Lake City, UT, ³Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: The 2013 classification criteria for systemic sclerosis (SSc) provide 3 points (towards a 9 point diagnosis) for patients who have an anti-topoisomerase I (anti-Scl-70)…
Abstract Number: 2155 • 2015 ACR/ARHP Annual Meeting
Inhibition of Sphingosine-1-Phosphate Signaling By AB22 As a Novel Strategy in the Treatment of Pulmonary Fibrosis Associated with Scleroderma
Ilia Atanelishvili¹, Yuichiro Shirai², Tanjina Akter³, Erik Stolarzewicz⁴, Rolf E Swenson⁵, Richard Silver⁶ and Galina S. Bogatkevich⁷, ¹Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ²Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ³Medical University of South Carolina, charleston, SC, ⁴Chem-Master International Inc, Stony Brook, NY, ⁵Arroyo BioSciences, Silver Spring, MD, ⁶Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁷Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Activation of sphingosine-1-phosphate (S1P) signaling has been extensively documented in various fibrotic conditions including pulmonary fibrosis. The aim of this study was to provide…
Abstract Number: 854 • 2012 ACR/ARHP Annual Meeting
Anti-EIF2B: A Novel Interstitial Lung Disease Associated Autoantibody in Patients with Systemic Sclerosis
Zoe Betteridge¹, Felix Woodhead², Christopher Bunn³, Christopher D. Denton⁴, David J. Abraham⁵, Sujal Desai⁶, Roland du Bois⁷, Athol U. Wells⁸ and Neil McHugh⁹, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Respiratory, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ³Immunology, Royal Free Hospital, London, United Kingdom, ⁴Department of Rheumatology, Royal Free and University College Medical School, London, England, ⁵UCL Medical School, London, United Kingdom, ⁶Radiology, Kings College Hosptial, London, United Kingdom, ⁷National Jewish Health, Denver, ⁸Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Autoantibodies occur in 75-95% of Systemic Sclerosis (SSc) patients. Studies have shown that the presence of particular SSc-specific autoantibodies (anti-centromere, anti-topoisomerase-1, anti-RNA polymerase III,…
Abstract Number: 785 • 2012 ACR/ARHP Annual Meeting
Resident Lung Fibroblast Gene Expression Signatures Predict Susceptibility or Resistance to Experimental Lung Fibrosis
Emma Derrett-Smith¹, Rachel Hoyles¹, Korsa Khan², David J. Abraham³ and Christopher P. Denton², ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ³UCL Medical School, London, United Kingdom
Background/Purpose: In scleroderma (SSc), lung fibrosis is linked to epithelial damage and dysregulated repair mechanisms. Resident lung fibroblasts may affect multiple cell types including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].